Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), highlights how research communities have self-organized in light of recent changes.
Research collaboration between Tufts and the Society for Clinical Research Sites explores the prevalence of this belief in ...
The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discusses how companies in ...
Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...
The combination met its primary endpoint of percent weight loss following an 8-week treatment period.
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...
Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...
Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback